The stock has a 36-month beta value of 3.19. Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRBP is 10.70M, and at present, short sellers hold a 17.47% of that float. On July 10, 2025, the average trading volume of CRBP was 165.48K shares.
CRBP) stock’s latest price update
The stock price of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has jumped by 11.01% compared to previous close of $7.54. Despite this, the company has seen a gain of 16.90% in its stock price over the last five trading days. globenewswire.com reported 2025-06-25 that NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors (the Phase 1 Western study). Participants in this arm of the study are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts in combination with Keytruda® (pembrolizumab).
CRBP’s Market Performance
Corbus Pharmaceuticals Holdings Inc (CRBP) has experienced a 16.90% rise in stock performance for the past week, with a -9.32% drop in the past month, and a 60.65% rise in the past quarter. The volatility ratio for the week is 6.41%, and the volatility levels for the past 30 days are at 6.64% for CRBP. The simple moving average for the past 20 days is 3.05% for CRBP’s stock, with a -26.97% simple moving average for the past 200 days.
Analysts’ Opinion of CRBP
Wedbush gave a rating of “Outperform” to CRBP, setting the target price at $85 in the report published on July 30th of the previous year.
CRBP Trading at 8.00% from the 50-Day Moving Average
After a stumble in the market that brought CRBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.48% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRBP starting from Jenkins John Kenneth, who sale 2,783 shares at the price of $7.35 back on May 30 ’25. After this action, Jenkins John Kenneth now owns 33 shares of Corbus Pharmaceuticals Holdings Inc, valued at $20,465 using the latest closing price.
Altmeyer Anne, the Director of Corbus Pharmaceuticals Holdings Inc, sale 1,392 shares at $7.25 during a trade that took place back on May 30 ’25, which means that Altmeyer Anne is holding 1,391 shares at $10,096 based on the most recent closing price.
Stock Fundamentals for CRBP
The total capital return value is set at -0.46. Equity return is now at value -44.89, with -37.86 for asset returns.
Based on Corbus Pharmaceuticals Holdings Inc (CRBP), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -17.6. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -56.99.
Currently, EBITDA for the company is -37.74 million with net debt to EBITDA at 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.82.
Conclusion
To sum up, Corbus Pharmaceuticals Holdings Inc (CRBP) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
